A little-known biotech firm focused on Traditional Chinese Medicine has surged over 64,000%, catapulting its valuation to nearly $10 billion. Is this a biotech breakthrough, a speculative frenzy, or something in between?

Join Dan Koh and Ryan Huang as they dissect the rise of Regencell Bioscience Holdings Limited — a company with just 12 employees, no FDA-approved products, and a CEO earning $1 a year.

See omnystudio.com/listener for privacy information.